Citations

Clear

13603 citation(s) found for "_, _".

A Multisite, 6-Month, Open-Label Study of Maintenance Transcranial Magnetic Stimulation for Adolescents with Treatment-Resistant Depression
Garzon, Juan F. , Elmaadawi, Ahmed Z. , Aaronson, Scott T., Schrodt, G. Randolph, Holbert, Richard C., Zuckerman, Seth, Demitrack, Mark A. , Strawn, Jeffrey R. , Croarkin, Paul E. , Croarkin, Paul E , Strawn, Jeffrey R , Aaronson, Scott T.

Mayo Clinic

Journal of Child and Adolescent Psychopharmacology | December 24, 2024 | Volume: 35 | Issue: 2 | Pages: 99-108

10.1089/cap.2024.0067 | PMID 39718805 Get It

Introduction: Transcranial magnetic stimulation (TMS) is a promising intervention for adolescents with treatment-resistant depression (TRD). However, the durability of TMS-related improvement in adolescents is unclear. This 6-month study followed adolescents with TRD who had responded to TMS and provided TMS retreatment for adolescents with a partial relapse. Methods: The study enrolled adolescents (12–21 years) with TRD who had at least a partial response to sham or active TMS in a randomized controlled trial. Partial response was defined as ≥25% reduction of Hamilton Depression Rating Scale-24 (HAMD24). Participants with a partial relapse (≥1 point increase in Clinical Global Impression–Severity) received retreatment with daily 10 Hz TMS sessions until depressive symptom severity returned to the baseline score or after 30 TMS treatments. Results: There were 84 eligible participants, 66 were enrolled, and 41 completed the 6-month study. Twenty-eight participants (42%) were retreated with TMS. TMS retreatment courses had a mean of 22 sessions. At the 6-month follow-up, the complete sample exhibited reduced depressive symptoms (mean HAMD24 of 5.24) compared with baseline at entry into follow-up (mean HAMD24 of 8.21). Baseline depressive symptom severity was positively correlated with the risk of partial relapse, while the number of previous TMS interventions showed no correlation with the risk of partial relapse. TMS was well tolerated. Conclusions: This is the largest, long-term follow-up study with TMS retreatment for adolescents with TRD. These findings demonstrate the feasibility and clinical effects of a TMS retreatment protocol for adolescents with TRD, following a standard course of acute TMS.
Liver Stiffness, Not Steatosis, Predicts Mortality in MASLD Patients: An NHANES Analysis
Yan, Yan , Antwi, Samuel O. , Badurdeen, Dilhana, Antwi, Samuel O , Yan, Yan , Huang, Yuting , Wang, Yichen, Liu, Yang

Mayo Clinic

Livers | December 24, 2024 | Volume: 4 | Issue: 4 | Pages: 711-719

10.3390/livers4040049 Get It

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) has surged as a major cause of liver transplants in the United States. Existing studies have presented conflicting findings regarding the association between liver characteristics (specifically steatosis and fibrosis) and mortality. This study investigates the relationship between the controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) via vibration-controlled transient elastography (VCTE) and all-cause mortality in MASLD patients. Methods: Using the NHANES 2017-2018 database, 3821 individuals representing the United States population with MASLD underwent VCTE for liver stiffness measurement. Exclusion criteria were applied, eliminating ineligible cases, incomplete examinations, underage individuals, and those with hepatitis B or C, along with significant alcohol consumption history. Cox proportional hazard models assessed the hazard ratio (HR) for all-cause mortality in CAP and LSM. Cox regression analysis with interaction terms was employed for deeper exploration. Results: The study unveiled a strong, independent correlation between LSM and all-cause mortality. However, the CAP failed to demonstrate a significant association with mortality in both univariate and adjusted analyses, contrary to recent findings. The analysis underscores the importance of accurately measuring liver stiffness via VCTE in predicting adverse outcomes in MASLD patients, emphasizing the pivotal role of fibrosis in assessing mortality risk. Conclusion: This study reaffirms the robust link between liver fibrosis (measured through VCTE) and mortality among MASLD individuals. The absence of a significant association between steatosis (indicated by CAP) and mortality challenges recent research, urging further comprehensive investigations with larger cohorts to delineate steatosis’ precise impact on MASLD-related mortality.
Laser Ablation of an Isolated External Auditory Canal Skin Wedge
Lakpa, Koffi L. , Eyassu, Daniel G. , Wiedermann, Joshua P.

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | December 24, 2024 | Volume: 134 | Issue: 5 | Pages: 366-369

10.1177/00034894241309219 | PMID 39716813 Get It

Introduction: External ear malformations represent a spectrum of congenital anomalies that may involve the external auditory canal (EAC), tympanic membrane (TM), or associated structures. A rare anomaly, the EAC skin wedge, results from incomplete canalization during embryologic development. This report presents the clinical presentation, diagnostic evaluation, and surgical management of this condition. Objective: To detail the successful surgical management of an isolated EAC skin wedge and demonstrate the applicability of argon laser in treating these congenital anomalies. Methods: A 13-month-old female presented with recurrent otitis media and mild bilateral conductive hearing loss. Physical examination revealed a fan-like skin wedge spanning the EAC to the TM. Imaging with temporal bone computed tomography confirmed the extent of the anomaly. Under general anesthesia, the skin wedge was ablated using an argon laser, followed by antibiotic-soaked packing to prevent scarring and recurrence. Follow-up audiometry and endoscopic evaluations assessed outcomes. Results: The procedure was well-tolerated, with no intraoperative complications. At 3 weeks and 3 months postoperatively, no recurrence of the skin wedge was observed, and audiometry normalized. The patient demonstrated improved middle ear ventilation and resolution of conductive hearing loss. Conclusions: This case demonstrates the successful use of argon laser in the management of a rare congenital EAC anomaly. Argon lasers offer precise ablation and excellent hemostasis, making them a valuable option for similar cases. This report emphasizes the importance of tailored surgical approaches for rare pediatric ear malformations.
The Intraosseous Subarcuate Loop of Anterior Inferior Cerebellar Artery: Anatomic Management Guide, Single-Center MRI Study, and Scoping Review
Plou, Pedro , Athanasoulis, Filippos , Kollia, Sofia , Leonel, Luciano, Carlson, Matthew L. , Link, Michael J. , Peris‐Celda, Maria , De Bonis, Alessandro, Torregrossa, Fábio , Serioli, Simona , Leonel, Luciano César P C, Carlson, Matthew, Bonis, Alessandro De, Bauman, Megan M. J.

Mayo Clinic

Operative Neurosurgery | December 24, 2024 | Volume: 29 | Issue: 3 | Pages: 389-398

10.1227/ons.0000000000001474 | PMID 39716468 Get It

BACKGROUND AND OBJECTIVES: The intraosseous subarcuate loop (SL) is a unique variant of the anterior inferior cerebellar artery (AICA), where a loop of the artery is trapped in the petrous bone's subarcuate fossa (SF). Recognizing this variant is crucial for planning cerebellopontine angle (CPA) surgeries; however, data regarding its frequency and management vary in the published literature. A cohort from a single center was studied using MRI to assess its prevalence, and the findings were compared with the existing literature. In addition, an intraoperative guide for mobilizing the intraosseous AICA's SL was provided through a detailed step-by-step cadaveric dissection. METHODS: Two hundred fifty-eight patients who had undergone MRI scans of the CPA (516 sides) were retrospectively reviewed. MRIs displaying vascular loops visible in the axial view were analyzed using multiplanar reconstruction, and the intraosseous loop frequency was evaluated. A scoping review was undertaken to provide an overview of previously published data on its prevalence. One embalmed and latex-injected specimen with intraosseous AICA's SL was dissected through a retrosigmoid approach, and 1 surgical case was detailed, describing the procedure to release it. RESULTS: Intraosseous AICA's SL mobilization involves the identification of its entry and exit points within the petrous bone, dural incision to expose the SF, SF drilling, subarcuate artery division, and detaching the vascular loop. Preservation of a dural cuff is crucial to prevent vascular injury. We analyzed 258 brain MRIs (mean age 55 years, 42% male). The intraosseous AICA's SL was present in 4 of 516 evaluated CPAs (0.8%). The prevalence of the vascular anomaly in the reviewed literature using different radiological modalities ranged from 0.2% to 1.6%. CONCLUSION: The intraosseous AICA's SL is an uncommon anatomic variation detectable by MRI, posing an added risk in CPA surgery. Identifying and properly mobilizing it is crucial for safe vascular preservation.
Narrow, Broad, and Future Considerations for Populations with Non-English Language Preference
Chipman, S , Meagher, Karen M. , Barwise, Amelia , Chipman, Samantha Aubrey , Barwise, Amelia K , Meagher, Karen M

Mayo Clinic

The American Journal of Bioethics | December 23, 2024 | Volume: 25 | Issue: 1 | Pages: No page available

10.1080/15265161.2024.2441738 | PMID 39714250 Get It

Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD‐ADRD): Executive summary of recommendations for primary care
Clevenger, Carolyn , Karlawish, Jason , Lin, Pei‐Jung , Norman, Mary S., Onyike, Chiadi U. , Sano, Mary , Scanland, Susan, Carrillo, María C. , Atri, Alireza , Dickerson, Bradford Clark , Knopman, David S. , Norman, Mary

Mayo Clinic

Alzheimer's & Dementia | December 23, 2024 | Volume: 21 | Issue: 6 | Pages: No page available

10.1002/alz.14333 | PMID 39713942 Get It

Abstract US clinical practice guidelines for the diagnostic evaluation of cognitive impairment due to Alzheimer's disease (AD) or AD and related dementias (ADRD) are decades old and aimed at specialists. This evidence‐based guideline was developed to empower all—including primary care—clinicians to implement a structured approach for evaluating a patient with symptoms that may represent clinical AD/ADRD. Through a modified‐Delphi approach and guideline‐development process (7374 publications were reviewed; 133 met inclusion criteria) an expert workgroup developed recommendations as steps in a patient‐centered evaluation process. This summary focuses on recommendations, appropriate for any practice setting, forming core elements of a high‐quality, evidence‐supported evaluation process aimed at characterizing, diagnosing, and disclosing the patient's cognitive functional status, cognitive–behavioral syndrome, and likely underlying brain disease so that optimal care plans to maximize patient/care partner dyad quality of life can be developed; a companion article summarizes specialist recommendations. If clinicians use this guideline and health‐care systems provide adequate resources, outcomes should improve in most patients in most practice settings. Highlights US clinical practice guidelines for the diagnostic evaluation of cognitive impairment due to Alzheimer's disease (AD) or AD and related dementias (ADRD) are decades old and aimed at specialists. This evidence‐based guideline was developed to empower all—including primary care—clinicians to implement a structured approach for evaluating a patient with symptoms that may represent clinical AD/ADRD. This summary focuses on recommendations, appropriate for any practice setting, forming core elements of a high‐quality, evidence‐supported evaluation process aimed at characterizing, diagnosing, and disclosing the patient's cognitive functional status, cognitive–behavioral syndrome, and likely underlying brain disease so that optimal care plans to maximize patient/care partner dyad quality of life can be developed; a companion article summarizes specialist recommendations. If clinicians use this guideline and health‐care systems provide adequate resources, outcomes should improve in most patients in most practice settings.
The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD‐ADRD): Executive summary of recommendations for specialty care
Clevenger, Carolyn , Karlawish, Jason , Lin, Pei‐Jung , Norman, Mary S., Onyike, Chiadi U. , Sano, Mary , Scanland, Susan, Carrillo, María C. , Dickerson, Bradford Clark , Atri, Alireza , Knopman, David S. , Norman, Mary

Mayo Clinic

Alzheimer's & Dementia | December 23, 2024 | Volume: 21 | Issue: 1 | Pages: No page available

10.1002/alz.14337 | PMID 39713957 Get It

Abstract US clinical practice guidelines for the diagnostic evaluation of cognitive impairment due to Alzheimer's disease (AD) or a related dementia (ADRD) are two decades old. This evidence‐based guideline was developed to empower all clinicians to implement a structured approach for evaluating a patient with symptoms that may represent clinical AD/ADRD. An expert workgroup conducted a review of 7374 publications (133 met inclusion criteria) and developed recommendations as steps in an evaluation process. This summary briefly reviews core recommendations and details specialist recommendations of a high‐quality, evidence‐supported evaluation process aimed at characterizing, diagnosing, and disclosing the patient's cognitive functional status, cognitive–behavioral syndrome, and likely underlying brain disease so that optimal care plans to maximize patient/care partner dyad quality of life can be developed; a companion article summarizes primary care recommendations. If clinicians use the recommendations in this guideline and health‐care systems provide adequate resources, outcomes should improve in most patients in most practice settings. Highlights US clinical practice guidelines for the diagnostic evaluation of cognitive impairment due to Alzheimer's disease (AD) or related dementias (ADRD) are decades old and aimed at specialists. This evidence‐based guideline was developed to empower all—including primary care—clinicians to implement a structured approach for evaluating a patient with symptoms that may represent clinical AD/ADRD. This summary focuses on recommendations appropriate for specialty practice settings, forming key elements of a high‐quality, evidence‐supported evaluation process aimed at characterizing, diagnosing, and disclosing the patient's cognitive functional status, cognitive–behavioral syndrome, and likely underlying brain disease so that optimal care plans to maximize patient/care partner dyad quality of life can be developed; a companion article summarizes primary care recommendations. If clinicians use this guideline and health‐care systems provide adequate resources, outcomes should improve in most patients in most practice settings.
The Alzheimer's Association clinical practice guideline for the diagnostic evaluation, testing, counseling, and disclosure of suspected Alzheimer's disease and related disorders (DETeCD‐ADRD): Validated clinical assessment instruments
Clevenger, Carolyn , Karlawish, Jason , Knopman, David S. , Lin, Pei‐Jung , Norman, Mary S., Onyike, Chiadi U. , Sano, Mary , Scanland, Susan, Carrillo, Marı́a C., Carrillo, María C. , Atri, Alireza , Dickerson, Bradford Clark , Knopman, David S. , Norman, Mary

Mayo Clinic

Alzheimer's & Dementia | December 23, 2024 | Volume: 21 | Issue: 1 | Pages: No page available

10.1002/alz.14335 | PMID 39713939 Get It

Abstract US clinical practice guidelines for the diagnostic evaluation of cognitive impairment due to Alzheimer's Disease (AD) or AD and related dementias (ADRD) are decades old and aimed at specialists. This evidence‐based guideline was developed to empower all—including primary care—clinicians to implement a structured approach for evaluating a patient with symptoms that may represent clinical AD/ADRD. As part of the modified Delphi approach and guideline development process (7374 publications were reviewed; 133 met inclusion criteria) an expert workgroup developed recommendations as steps in a patient‐centered evaluation process. The workgroup provided a summary of validated instruments to measure symptoms in daily life (including cognition, mood and behavior, and daily function) and to test for signs of cognitive impairment in the office. This article distills this information to provide a resource to support clinicians in the implementation of this approach in clinical practice. The companion articles provide context for primary care and specialty clinicians with regard to how to fit these instruments into the workflow and actions to take when integration of performance on these instruments with clinical profile and clinician judgment support potential cognitive impairment.
Evaluating the Role of Aspirin in Liver Disease: Efficacy, Safety, Potential Benefits and Risks
Elshaer, Amani , Lizaola-Mayo, Blanca C, Lizaola‐Mayo, Blanca

Mayo Clinic

Life | December 23, 2024 | Volume: 14 | Issue: 12 | Pages: 1701

10.3390/life14121701 | PMID 39768407 Get It

The rise in liver disease incidence and prevalence has led to increasing morbidity and mortality worldwide. Persistent hepatic inflammation drives disease progression by increasing fibrosis, advancing to cirrhosis, and potentially developing into hepatocellular carcinoma (HCC). Addressing these complications is essential to reduce liver-related mortality. Recent studies suggest that non-steroidal anti-inflammatory drugs, particularly aspirin, may play a beneficial role in managing liver disease. Aspirin’s anti-inflammatory and chemoprotective effects contribute to slowing disease progression and reducing the risks associated with chronic liver disease (CLD). This review highlights the current literature on the effects of aspirin in CLD, with a focus on patients with metabolic-associated steatotic liver disease (MASLD) and hepatitis B and C. We will examine aspirin’s potential ability to mitigate fibrosis, reduce the incidence of HCC, and lower liver-related mortality. Additionally, we will discuss its potential side effects and safety considerations, particularly in the context of liver disease, where there is an increased risk of bleeding.
Autoimmune brainstem encephalitis: Clinical associations, outcomes, and proposed diagnostic criteria
Gilligan, Michael , Thakolwiboon, Smathorn , Orozco, Emma, Banks, Samantha A. , López‐Chiriboga, A. Sebastian , Tillema, Jan‐Mendelt , Mills, John R. , Pittock, Sean J. , Valencia-Sánchez, Cristina , Ζεκερίδου, Αναστασία , Dubey, Divyanshu , Dubey, Divyanshu , Pittock, S J , Banks, Samantha , Lopez-Chiriboga, A Sebastian , Valencia Sanchez, Cristina , Zekeridou, Anastasia , Dubey, Divyanshu , McKeon, Andrew , Dubey, Divyanshu , Gilligan, Michael , Thakolwiboon, Smathorn , Flanagan, Eoin P. , McKeon, Andrew

Mayo Clinic

Annals of Clinical and Translational Neurology | December 21, 2024 | Volume: 12 | Issue: 1 | Pages: 213-225

10.1002/acn3.52273 | PMID 39708293 Get It

AbstractObjectiveWe describe neurologic phenotype, clinical associations, and outcomes in autoimmune brainstem encephalitis.MethodsMedical records of neural‐IgG positive autoimmune brainstem encephalitis patients diagnosed at Mayo Clinic (January 1, 2006–December 31, 2022) were reviewed.ResultsNinety‐eight patients (57 male) were included. Median age of symptom onset was 51 years (range, 8 months‐85 years). Frequent presenting features were ≥1: diplopia (80%), ataxia (78%), dysarthria (68%), vestibulocochlear symptoms (67%), dysphagia (61%), nausea/vomiting (42%), and facial weakness (32%). Altered mental status (11%) was uncommon. Neural antibodies detected were as follows: KLHL‐11 (26 patients), GAD65 (high titer, 12), ANNA‐1 (anti‐Hu, 8), ANNA‐2 (anti‐Ri, 8), Ma2 (7), IgLON‐5 (6), AQP4 (6), MOG (4), glycine receptor (4), GQ1B (4), PCA‐1 (anti‐Yo, 4), DPPX (2), neurochondrin (2), neurofilament (2), NMDA‐R (2), AGNA‐1 (SOX‐1, 1), ANNA‐3 (DACH1, 1), amphiphysin (1), CRMP‐5 (1), ITPR‐1 (1), PCA‐Tr (DNER, 1), and PDE10A (1). Cancer was identified in 55 patients: germ cell (23 patients; 3 extra‐testicular), ductal breast adenocarcinoma (8), small cell carcinoma (6, lung 4), adenocarcinomas (6), neuroendocrine carcinoma (3), hematologic (2), squamous cell (2), and other (7). Median modified Ranking score (mRS) at last follow‐up was 3 (range, 0–6). Factors associated with poor outcome included abnormal brain MRI, bulbar symptoms, and elevated CSF IgG index. Kaplan–Meier analysis revealed faster progression to wheelchair in patients who were immunotherapy refractory and with elevated CSF IgG index. Diagnostic criteria for autoimmune brainstem encephalitis (definite and probable) are proposed.InterpretationAutoimmune brainstem encephalitis is a distinct clinical subphenotype of autoimmune encephalitis. Abnormal brain MRI, bulbar symptoms, and elevated CSF‐IgG index associate with poor outcome.